Fate Therapeutics Inc. (FATE)

19.72
0.68 3.57
NASDAQ : Health Technology
Prev Close 19.04
Open 19.22
Day Low/High 18.92 / 19.99
52 Wk Low/High 8.64 / 20.84
Volume 701.96K
Avg Volume 716.20K
Exchange NASDAQ
Shares Outstanding 65.19M
Market Cap 1.30B
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Fate Therapeutics (FATE) Shares Cross Above 200 DMA

Fate Therapeutics (FATE) Shares Cross Above 200 DMA

In trading on Wednesday, shares of Fate Therapeutics Inc crossed above their 200 day moving average of $12.19, changing hands as high as $12.21 per share. Fate Therapeutics Inc shares are currently trading up about 5.8% on the day.

Interesting FATE Put And Call Options For January 2019

Interesting FATE Put And Call Options For January 2019

Investors in Fate Therapeutics Inc saw new options begin trading this week, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FATE options chain for the new January 2019 contracts and identified one put and one call contract of particular interest.

First Week Of FATE December 21st Options Trading

First Week Of FATE December 21st Options Trading

Investors in Fate Therapeutics Inc saw new options become available this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FATE options chain for the new December 21st contracts and identified one put and one call contract of particular interest.

Fate Therapeutics (FATE) Shares Cross Below 200 DMA

Fate Therapeutics (FATE) Shares Cross Below 200 DMA

In trading on Friday, shares of Fate Therapeutics Inc crossed below their 200 day moving average of $8.74, changing hands as low as $8.65 per share. Fate Therapeutics Inc shares are currently trading down about 5.4% on the day.

Fate Therapeutics Enters Oversold Territory (FATE)

Fate Therapeutics Enters Oversold Territory (FATE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Traders Are Still Finding Plenty of Stocks That They Want to Buy

Traders Are Still Finding Plenty of Stocks That They Want to Buy

Sentiment is very positive, regardless of what the indices may say.

Biotech Sector Steps Up to Provide Some Strong Action for Traders

Biotech Sector Steps Up to Provide Some Strong Action for Traders

The S&P 500 has shown the same pattern for three consecutive days.

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

Fate Therapeutics Announces Initial Clinical Data Of FATE-NK100 For Recurrent Ovarian Cancer At The Innate Killer Summit 2018

Fate Therapeutics Announces Initial Clinical Data Of FATE-NK100 For Recurrent Ovarian Cancer At The Innate Killer Summit 2018

Stable Disease with Tumor Shrinkage Reported in Subject 2 Following Single Dose of NK100

Interesting FATE Put And Call Options For November 16th

Interesting FATE Put And Call Options For November 16th

Investors in Fate Therapeutics Inc saw new options begin trading this week, for the November 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Fate Therapeutics Announces Receipt Of CIRM Grant For Clinical Translation Of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy

Fate Therapeutics Announces Receipt Of CIRM Grant For Clinical Translation Of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy

$4.0 Million Awarded by CIRM to Support Advancement of First-of-Kind NK Cell Product Candidate derived from a Master Engineered iPSC Line

Fate Therapeutics Reaches Analyst Target Price

Fate Therapeutics Reaches Analyst Target Price

In recent trading, shares of Fate Therapeutics Inc have crossed above the average analyst 12-month target price of $9.40, changing hands for $10.59/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Fate Therapeutics Announces First Subject Treated With FATE-NK100 In DIMENSION Study For Advanced Solid Tumors

Fate Therapeutics Announces First Subject Treated With FATE-NK100 In DIMENSION Study For Advanced Solid Tumors

First Clinical Trial Investigating the Combination of Allogeneic Donor NK Cell Therapy and FDA-Approved Targeted Monoclonal Antibody Therapy for Solid Tumor Malignancies

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Here's what you need to know now for Monday, Jan. 22.

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.

Commit To Purchase Fate Therapeutics At $5, Earn 20% Annualized Using Options

Commit To Purchase Fate Therapeutics At $5, Earn 20% Annualized Using Options

Investors eyeing a purchase of Fate Therapeutics Inc shares, but cautious about paying the going market price of $6.38/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $5 strike, which has a bid at the time of this writing of 60 cents.

TheStreet Quant Rating: D (Sell)